Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Revisits Priorities: GMPs Awarded Same Status As R&D, Marketing

Executive Summary

Lilly is rearranging its operating priorities to put manufacturing processes on the same level as R&D and sales and marketing, CEO Sidney Taurel told investors
Advertisement

Related Content

FDA Drug Development Efforts Are “Revolutionary,” Lilly’s Taurel Says
Lilly GMPs Clear One Milestone; Cymbalta Launch Now Planned For Summer
Wyeth Manufacturing Improvements Extend To Drug R&D, Exec Says
Schering Moves Forward On GMP Work Plan; Is Marketing Settlement Next?
Schering Moves Forward On GMP Work Plan; Is Marketing Settlement Next?
Lilly GMPs Will Not Deter Product Rollout, Firm Says
FDA GMP Initiative Shifts Warning Letter Review Back To Agency Centers
Lilly Cialis Using Alternate Manufacturing Facilities For 2nd Half 2003 Launch
Lilly GMP “Culture Change” Will Address Compliance Issues, Firm Tells FDA
Zyprexa IM Manufacturing Issues To Be Discussed By FDA, Lilly March 15
Advertisement
UsernamePublicRestriction

Register

PS042093

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel